FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313207902> ?p ?o ?g. }

• W4313207902 endingPage "10" @default.
• W4313207902 startingPage "1" @default.
• W4313207902 abstract "Data presented at ASCO 2022 provide new perspectives of therapy for patients with breast cancer. Starting with the plenary session with DESTINY-Breast04 we are turning a new page in the treatment of metastatic human epidermal growth factor receptor 2 (HER2)-low breast cancer patients. The results of the DESTINY-Breast04 trial open a new therapeutic option for half of the patients with metastatic breast cancer, establishing HER2-low metastatic breast cancer as a targetable population with trastuzumab deruxtecan. The indications for antibody drug conjugates are expanding to patients with metastatic hormone receptor positive endocrine resistant disease based on TROPICS-02. From the multitude of clinical trials with antibody drug conjugates, we can envision that this will be likely the new way to deliver chemotherapy in the future. Differences in survival within the three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in upfront metastatic hormone positive breast cancer are emerging. We have data on continuation of ribociclib beyond disease progression on CDK4/6 in the MAINTAIN trial. The FAKTION trial does prove the benefit of the AKT inhibitor capivasertib and does highlight the importance of an extended molecular panel of the phosphatidylinositol3-kinase PI3K pathway. Furthermore, the exploratory analysis of KEYNOTE- 522, examining the correlation of event free survival and residual cancer burden after neoadjuvant treatment in patients with triple negative breast cancer does demonstrate a benefit of pembrolizumab extending to patient which did not achieve pathologic complete response, mainly by a decrease in residual cancer burden. Advances in biomarkers of response to immunotherapy are needed. For early stage breast cancer studies are in support of de-escalation of radiotherapy for low risk breast cancer patients and confirming the lack of benefit of adjuvant chemotherapy for elderly patients, even with high genomic grade index." @default.
• W4313207902 created "2023-01-06" @default.
• W4313207902 creator A5084174428 @default.
• W4313207902 date "2022-12-01" @default.
• W4313207902 modified "2023-10-01" @default.
• W4313207902 title "ASCO 2022 Breast Cancer Updates" @default.
• W4313207902 cites W2152811375 @default.
• W4313207902 cites W2314772071 @default.
• W4313207902 cites W2387397851 @default.
• W4313207902 cites W2618058692 @default.
• W4313207902 cites W2806889698 @default.
• W4313207902 cites W2909799373 @default.
• W4313207902 cites W2914282788 @default.
• W4313207902 cites W2922684335 @default.
• W4313207902 cites W2944687997 @default.
• W4313207902 cites W2990876124 @default.
• W4313207902 cites W2994917610 @default.
• W4313207902 cites W3018222852 @default.
• W4313207902 cites W3041271367 @default.
• W4313207902 cites W3087393791 @default.
• W4313207902 cites W3095107109 @default.
• W4313207902 cites W3098994343 @default.
• W4313207902 cites W3119128530 @default.
• W4313207902 cites W3165576985 @default.
• W4313207902 cites W3168050868 @default.
• W4313207902 cites W3168654539 @default.
• W4313207902 cites W3201764922 @default.
• W4313207902 cites W3205002341 @default.
• W4313207902 cites W4210373123 @default.
• W4313207902 cites W4210684267 @default.
• W4313207902 cites W4220744079 @default.
• W4313207902 cites W4220923708 @default.
• W4313207902 cites W4221057282 @default.
• W4313207902 cites W4221085715 @default.
• W4313207902 cites W4229010465 @default.
• W4313207902 cites W4229070154 @default.
• W4313207902 cites W4229079181 @default.
• W4313207902 cites W4281624688 @default.
• W4313207902 cites W4281633190 @default.
• W4313207902 cites W4281640394 @default.
• W4313207902 cites W4281646658 @default.
• W4313207902 cites W4281664688 @default.
• W4313207902 cites W4281694026 @default.
• W4313207902 cites W4281753909 @default.
• W4313207902 cites W4282047635 @default.
• W4313207902 cites W4283574504 @default.
• W4313207902 cites W4284712928 @default.
• W4313207902 cites W4289916338 @default.
• W4313207902 cites W4293083585 @default.
• W4313207902 cites W4293083647 @default.
• W4313207902 cites W4295837535 @default.
• W4313207902 cites W4297986229 @default.
• W4313207902 cites W4297986284 @default.
• W4313207902 doi "https://doi.org/10.53011/jmro.2022.02.02" @default.
• W4313207902 hasPublicationYear "2022" @default.
• W4313207902 type Work @default.
• W4313207902 citedByCount "1" @default.
• W4313207902 countsByYear W43132079022023 @default.
• W4313207902 crossrefType "journal-article" @default.
• W4313207902 hasAuthorship W4313207902A5084174428 @default.
• W4313207902 hasBestOaLocation W43132079021 @default.
• W4313207902 hasConcept C121608353 @default.
• W4313207902 hasConcept C126322002 @default.
• W4313207902 hasConcept C143998085 @default.
• W4313207902 hasConcept C2775930923 @default.
• W4313207902 hasConcept C2777701055 @default.
• W4313207902 hasConcept C2778311097 @default.
• W4313207902 hasConcept C2779744173 @default.
• W4313207902 hasConcept C2779786085 @default.
• W4313207902 hasConcept C2780057760 @default.
• W4313207902 hasConcept C2908647359 @default.
• W4313207902 hasConcept C530470458 @default.
• W4313207902 hasConcept C535046627 @default.
• W4313207902 hasConcept C71924100 @default.
• W4313207902 hasConcept C99454951 @default.
• W4313207902 hasConceptScore W4313207902C121608353 @default.
• W4313207902 hasConceptScore W4313207902C126322002 @default.
• W4313207902 hasConceptScore W4313207902C143998085 @default.
• W4313207902 hasConceptScore W4313207902C2775930923 @default.
• W4313207902 hasConceptScore W4313207902C2777701055 @default.
• W4313207902 hasConceptScore W4313207902C2778311097 @default.
• W4313207902 hasConceptScore W4313207902C2779744173 @default.
• W4313207902 hasConceptScore W4313207902C2779786085 @default.
• W4313207902 hasConceptScore W4313207902C2780057760 @default.
• W4313207902 hasConceptScore W4313207902C2908647359 @default.
• W4313207902 hasConceptScore W4313207902C530470458 @default.
• W4313207902 hasConceptScore W4313207902C535046627 @default.
• W4313207902 hasConceptScore W4313207902C71924100 @default.
• W4313207902 hasConceptScore W4313207902C99454951 @default.
• W4313207902 hasIssue "2" @default.
• W4313207902 hasLocation W43132079021 @default.
• W4313207902 hasOpenAccess W4313207902 @default.
• W4313207902 hasPrimaryLocation W43132079021 @default.
• W4313207902 hasRelatedWork W1963982224 @default.
• W4313207902 hasRelatedWork W2066747782 @default.
• W4313207902 hasRelatedWork W2092591992 @default.
• W4313207902 hasRelatedWork W2146983958 @default.
• W4313207902 hasRelatedWork W2147874203 @default.

• next